title: Macular edema associated with gyrate atrophy managed with intravitreal triamcinolone: a case report.
abstract: OBJECTIVE
  To describe the use of 4 mg intravitreal triamcinolone acetonide (IVTA) for gyrate atrophy-related macular edema (ME) and to report anatomic and functional outcomes, during a nine-month period.
  
  
  METHODS
  A 27-year-old female complained of decreased vision since diagnosis of gyrate athrophy (GA), six years before admission. At presentation visual acuity was 20/100 in OD and 20/80 in OS. Ophthalmological examination disclosed significant cataract in OD, pseudophakia in OS and typical GA findings. Fluorescein angiography (FA) disclosed ME that was confirmed by optical coherence tomography (OCT), which also showed subfoveal fluid. OS was treated with a 4-mg IVTA injection. One month later, vision improved to 20/50+1 and foveal thickness decreased, with less leakage in FA. This picture was maintained up to six months, when there was recurrence of ME to a level similar to the baseline. At nine months, visual acuity dropped to 20/80, and ME was maintained, with remodeling in macular profile.
  
  
  CONCLUSIONS
  There is a transient therapeutic effect with 4-mg IVTA injection for GA-related ME. After drug clearance, edema recurs, with return of visual acuity to pretreatment level.
authors.affiliation: Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. dvitor@ufmg.br
authors.forename: Daniel Vítor
authors.initials: DV
authors.lastname: Vasconcelos-Santos
authors.forename: Erika Pacheco
authors.initials: EP
authors.lastname: Magalhães
authors.forename: Márcio Bittar
authors.initials: MB
authors.lastname: Nehemy
mesh_terms: D000328:Adult; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D015799:Gyrate Atrophy / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D012008:Recurrence; D013997:Time Factors; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000627:therapeutic use*; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide